Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
This is all leading up to our presence and sales in USA......and our NASDAQ listing.
Ducks lining up nicely
funding was 1/5 for testing, the rest for cancer treatment.
this is good news, but not fantastic. No commercial deal, and no pathway outlined for one. Too much soft soap waffle, just tell it like it is, what we can expect. What happens next in this process, does it need to be validated with another entity, can the results be used with other players, etc.
being a ARM model is great but the channels have the power and control, not the suppliers.
I think that the typo testes instead of tests could have been prophetic as most of the RNSs we have been fed for months are a positive and constructive load of boll**cks masquerading as progress but concealing a failure to deliver the near perfect RFT promised for the autumn on which the current share price is based. So -10p today's. Well done AS.
Go read todays GDR RNS that at one point had its price up 35% this morning.
Distribution deal in USA and Europe for an automated rapid PCR test, do see the advantage of using BAMs machines but the PCR crews will not go away without a fight.
GKB - perhaps the problem was the bullishness from AS during the Summer - but then that bullishness secured $50m and secured our immediate future without need for (significant) dilution.
If they had said back in Q2 20 that development of tests had started and by Q1 21 we should have testes to market - I doubt they would have secured $50m at 120. Perhaps AS really did believe tests would be on the market by Q3 20?
Bruker are also selling NCYT test, so maybe a better route to market or are we going to be replacing theirs!! Just my thoughts. LTH
Good post Wiggly, I agree.
There is good chance BAM’s has been on a small trial with Bruker since October 2020 via Adeptrix, as you say Bruker liked the results and invest in Adeptrix and Avacta get the official partnership.
No worries about BAM’s not working then, ditto how much ££ is this going to bring in until a firm contract?
We won’t be doing it for free, so at least it’s revenue generating.
Gkb,
All entitled to opinion but I think given what we know this product will definitely now be delivered to market - with the backing of a GIANT
1. Adeptrix + AVCT collaboration and product developed clearly excited Bruker
2. Adeptrix + AVCT + Bruker evaluated the product together (see Bruker research paper, we know it works...)
3. Bruker takes a stake in Adeptrix for reasons stated - to accelerate collaborations with producers of affinity reagents
4. ACVT announce a partnership with Bruker
Given point 2 above, why would point 4 now follow?
I would think that following CV the commercial details will follow. AS has always spoken of significant commercial progress with a partner capable to deliver BAMS at scale.
It is taking ages, it is frustrating as hell, but hard to deny that it will happen. While many had a squeeky bum when the vaccine news hit, I think we all now accept testing will be here throughout 2021-22 and this is a good low cost method that can be used for mass screening.
We knew this 9 months ago though, and that is the problem..
I think the partnership is a great move in that the test is best placed when it has the machine manufacturers backing.
Yes - seems clear to me that they are looking for BAMS to take over from, not just complement, PCR testing. I think the market for BAMS could be far larger than most of us have realised.
I thought we would be further alone than we are by now, but I wouldn’t call this “jam tomorrow” - very clear route to market now and won’t be long until sales start.
Exactly, far more accurate and less costly than PCR - This could be HUGE!
"exceeding the capacity of the commonly used PCR machines, making BAMS a potentially very attractive high throughput technique for COVID-19 screening in the clinical setting."
Biden spending $50 billion on covid testing and this test will be taking part of that through this agreement with one of the big players.
Guys and Girls,
You can deramp all you want but the facts are clear. Little AVCT has just partnered with a monster $9B MC Bruker and the reason is that AVCT, partnered with Adeptrix, can deliver a GOLD STANDARD Covid test solution with exquisite S&S.
Validation of a gold standard solution clearly takes time however, even the greatest pessimist surely cant deny that it is 100% coming. When it comes, it will be truly transformational for AVCT with global validation of the Affimers technology.
Don't forget that BRUKER recently invested directly in Adeptrix, taking a minority stake for the the following reasons;
-------
1. Dr. Rohan A. Thakur, EVP of Life Sciences Mass Spectrometry at Bruker Daltonics, commented: “Our partnership is expected to ACCELERATE COLLABORATIONS with DEVELOPERS of antibodies and other AFFINITY (E.G> AFFIMER) REAGENTS
and
2. Dr. Vladislav Bergo, Chief Executive Officer at Adeptrix, said: "We are excited to partner with Bruker to pursue the next stage in our company’s growth and make Adeptrix products available to customers WORLWIDE!